Palivizumab: A debate about funding

Journal of Paediatrics and Child Health

Volumn 48, Issue 5, 2012, Pages 373-377

  Fitzgerald, Dominic A ^a,b   Isaacs, David ^a,b   Tobin, Bernadette ^c,d  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

cost effectiveness; equity; immunoglobulin; RSV

Indexed keywords

CORTICOSTEROID; OXYGEN; PALIVIZUMAB;

ARTIFICIAL VENTILATION; BIRTH WEIGHT; CHRONIC LUNG DISEASE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; ETHICIST; FUNDING; GESTATIONAL AGE; HUMAN; INFECTION PREVENTION; MEDICAL ETHICS; NOSE FEEDING; PATENT DUCTUS ARTERIOSUS; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; PULMONARY ASPIRATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SYSTEMIC THERAPY; VIRUS TRANSMISSION; VOCAL CORD PARALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; AUSTRALIA; BRONCHOPULMONARY DYSPLASIA; COST-BENEFIT ANALYSIS; DRUG COSTS; FINANCING, ORGANIZED; HEALTH CARE RATIONING; HOSPITAL COSTS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PHARMACY AND THERAPEUTICS COMMITTEE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84861145956     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2010.01865.x     Document Type: Review

References (12)

1. Johnson S, Oliver C, Prince GA, et al,. Development of a humanised monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997; 176: 1215-24. (Pubitemid 27460986)
2. Subramanian KN, Weisman LE, Rhodes T, et al,. Safety, tolerance and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. 1998; 17: 110-5. (Pubitemid 28096007)
3. Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduced hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531-7.
4. Feltes TF, Cabalka AK, Meissner HC, et al,. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with haemodynamically significant congenital heart disease. J. Pediatr. 2003; 143: 532-40. (Pubitemid 37352516)
5. Fitzgerald DA,. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr. Respir. Rev. 2009; 10: 143-7.
6. Banjerji A, Lanctot KL, Paes BA, et al,. Comparison of the cost of hospitalisation for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr. Infect. Dis. J. 2009; 28: 702-6.
7. Teale A, Deshpande S, Burls A,. Palivizumab and the importance of cost-effectiveness. BMJ 2009; 338: 1474-6.
8. Singer P,. Why we must ration health care. New York Times 2009; 15 July.
9. Isaacs D, Fitzgerald D,. A seasonal cost-effectiveness analysis: the last Noel? BMJ 2002; 325: 1426.
10. Australian Government Department of Health and Ageing. The Australian Immunisation Handbook, 9th edn. Canberra, Australia: Australian Government Publishing, 2008. Available from: [accessed 9 December 2009].
11. Isaacs D,. Palivizumab. An example of indication creep. BMJ 2009; 339: b2724. doi: 10.1136/bmj.b2724.
12. Fisher A, Gormally L,. Healthcare Allocation: An Ethical Framework for Public Policy. London: The Linacre Centre, 2001.